Abstract
The purpose of the present study was two-fold. Firstly, to present a more comprehensive analysis of the disinhibitory effects of 5-HT1A receptor agonists after discrete dorsal raphe (DRN) injections (Higgins et al. 1988). Secondly, the effects of the 5-HT1B receptor agonist CGS12066B and the 5-HT1B/1C agonist mCPP were examined following injection into this nucleus. The increases in social interaction (SI) induced by intra-raphe injections of 8-OH DPAT (0.02–1 μg), buspirone (0.04–0.2 μg), ipsapirone (0.2 μg) and gepirone (0.2–1 μg) under a high light unfamiliar paradigm (HLU) were typically due to increased bout frequency, duration and a higher incidence of sniff, follow, allogroom behaviour. These increases were qualitatively similar to those seen in control animals tested under low light/familiar (LLF) conditions, thus supporting the belief that the drug-induced increases in SI reflected decreases in anxiety. Furthermore, at doses effective under the HLU condition, 8-OH DPAT, buspirone and gepirone failed to modify SI under conditions of minimal suppression (LLF paradigm). At doses which significantly increased punished responding in a water-lick conflict test 8-OH DPAT, ipsapirone and gepirone tended to also increase unpunished rates of drinking. However, in drug untreated rats, prior habituation to the test apparatus also increased unpunished drinking, suggesting some neophobia-induced suppression. At a comparatively high dose, the 5-HT1B agonist CGS12066B (2.5 μg), but not the putative 5-HT1B/1c agonist mCPP (0.5–12.5 μg), increased SI under the HLU condition. Considered along-side the other compounds described in this report, the relative potency of CGS12066B may be reflective of a 5-HT1A receptor interaction. Together, these data support the proposal that the DRN is an important site through wich 5-HT1A receptor agonists express their anxiolytic actions.
Similar content being viewed by others
References
Connor HE, Higgins GA (1990) Cardiovascular effects of 5-HT1A receptor agonists injected into the dorsal raphe nucleus of conscious rats. Eur J Pharmacol 182: 63–72
Critchley MAE, Handley SL (1987) Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology 93: 502–506
Csanalosi I, Schweizer E, Chase WG, Rickels K (1987) Gepirone in anxiety: a pilot study. J Clin Psychopharmacol 7: 31–33
Curzon G, Kennett GA (1990) mCPP: a tool for studying behavioural responses associated with 5-HT1c receptors. TIPS 11: 181–182
Dourish CT, Hutson PH, Curzon G (1986) Putative anxiolytics 8-OH DPAT, buspirone and TVXQ 7821 are agonists at 5-HT1A autoreceptors in the raphe nuclei. TIPS 7: 212–214
Eison AS, Eison MS, Stanley M, Riblet LA (1986) Serotonergic mechanism in the behavioural effects of buspirone and gepirone. Pharmacol Biochem Behav 24: 701–706
Engel JA, Hjorth S, Svensson K, Carlsson A, Liljequist S (1984) Anti-conflict effect of the putative serotonergic receptor agonist 8-OH DPAT. Eur J Pharmacol 105: 365–368
File SE (1980) The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2: 219–238
File SE (1985) Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. Neuropsychobiology 13: 55–62
Fletcher PJ, Davies M (1990) The involvement of 5-hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone. Br J Pharmacol 99: 519–525
Goa K, Ward A (1986) Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32: 114–129
Goldberg HL, Finnerty RJ (1979) Comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 136: 1184–1187
Gower AJ, Tricklebank MD (1988) Alpha2-adrenoceptor antagonist activity may account for the effects of buspirone in an anti-conflict test in the rat. Eur J Pharmacol 155: 129–137
Gozlan H, El Mestikaway S, Pichat L, Glowinski J, Hamon M (1983) Identification of pre-synaptic serotonin autoreceptors using a new ligand: [3H]-PAT. Nature 305: 140–142
Guy AP, Gardner CR (1985) Pharmacological characterization of a modified social interaction model of anxiety in the rat. Neuropsychobiology 13: 194–200
Higgins GA, Elliott PJ (1991) Differential behavioural activation following intra-raphe infusion of 5-HT1A drugs. Eur J Pharmacol 193: 351–356
Higgins GA, Bradbury AJ, Jones BJ, Oakley NR (1988) Behavioural and biochemical consequences following activation of 5-HT1-like and GABA receptors in the dorsal raphe nucleus of the rat. Neuropharmacology 27: 993–1001
Higgins GA, Jones BJ, Oakley NR, Tyers MB (1991) Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 antagonists. Psychopharmacology 104: 545–551
Hillegaart V (1991) Effects of local application of 5-HT and 8-OH DPAT into the dorsal and median raphe nuclei on core temperature in the rat. Psychopharmacology 103: 291–296
Hillegaart V, Hjorth S (1989) Median raphe, but not dorsal raphe, application of the 5-HT1A agonist 8-OH DPAT stimulates rat motor activity. Eur J Pharmacol 160: 303–307
Hutson PH, Sarna GS, O’Connell MT, Curzon G (1989) Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH DPAT into the nucleus raphe dorsalis. Neurosci Lett 100: 276–280
Iversen SD (1984) 5-HT and anxiety. Neuropharmacology 23: 1553–1560
Kennett GA, Whitton P, Shah K, Curzon G (1989) Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1c receptor antagonists. Eur J Pharmacol 164: 445–454
Meert TF, Colpaert FC (1986) The shock probe conflict procedure: a new assay responsive to benzodiazepines, barbiturates and related compounds. Psychopharmacology 88: 445–450
Moser PC (1989) An evaluation of the elevated plus-maze using the novel anxiolytic buspirone. Psychopharmacology 99: 48–53
Neale RF, Fallon SL, Boyar WC, Wasley JWF, Martin LL, Stone GA, Glaeser BS, Sinton CM, Williams M (1987) Biochemical and pharmacological characterization of CGS12066B, a selective serotonin-1B agonist. Eur J Pharmacol 136: 1–9
Oakley NR, Jones BJ (1983) Buspirone enhances [3H]-flunitrazepam binding in vivo. Eur J Pharmacol 87: 499–500
Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic Press, New York
Pellow S, Johnston AL, File SE (1987) Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG7142 using the elevated plusmaze test in the rat. J Pharm Pharmacol 39: 917–928
Pettibone DJ, Williams M (1984) Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 33: 1531–1535
Schoeffter P, Hoyer D (1989) Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn-Schmiedeberg’s Arch Pharmacol 339: 675–683
Schuurman T, Spencer DG, Traber J (1986) Behavioural effects of the 5-HT1A receptor ligand ipsapirone (TVXQ7821): a comparison with 8-OH DPAT and diazepam. Psychopharmacology 89: S54
Sharp T, Bramwell SR, Clark D, Grahame-Smith DG (1989a) In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. J Neurochem 53: 234–240
Sharp T, Bramwell SR, Grahame-Smith DG (1989b) 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 96: 283–290
Sinton CM, Fallon SL (1988) Electrophysiological evidence for a functional differentiation between subtypes of the 5-HT1 receptor. Eur J Pharmacol 157: 173–181
Soderpalm B, Hjorth S, Engel JA (1989) Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery’s conflict test. Pharmacol Biochem Behav 32: 259–265
Soubrie P (1986) Reconciling the role of central serotonin neurones in human and animal behaviour. Behav Brain Sci 9: 319–363
Sprouse JS, Aghjanian GK (1987) Electrophysiological response of serotonergic dorsal raphe neurones to 5-HT1A and 5-HT1B agonists. Synapse 1: 3–9
Traber J, Glaser T (1987) 5-HT1A receptor-related anxiolytics. TIPS 8: 432–437
Vandermaelen CP, Matheson GK, Wilderman RC, Patterson LA (1987) Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a nonbenzodiazepine anxiolytic drug. Eur J Pharmacol 129: 123–130
Verge D, Daval G, Marcinkiewicz M, Patey A, El Mestikaway M, Gozlan H, Hamon M (1986) Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J Neursci 6: 3474–3482
Vogel JR, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology 21: 1–7
Weissman-Nanopoulos D, Mach E, Magre J, Demassey Y, Pujol J-F (1985) Evidence for the localization of 5-HT1A binding sites on serotonin containing neurones in the raphe dorsalis and raphe centralis nuclei of the rat brain. Neurochem Int 7: 1061–1072
Whitton P, Curzon G (1990) Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology 100: 138–140
Wilkinson LO, Dourish CT (1991) Serotonin and animal behaviour. In: Peroutka SJ (ed) Serotonin receptor subtypes: basic and clinical aspects. Wiley-Liss, New York, pp 147–210
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Higgins, G.A., Jones, B.J. & Oakley, N.R. Effect of 5-HT1A receptor agonists in two models of anxiety after dorsal raphe injection. Psychopharmacology 106, 261–267 (1992). https://doi.org/10.1007/BF02801982
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02801982